No Data
PTC Brings AI-Powered PLM to Hannover Messe 2025 With Windchill AI
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating
Promising Potential of PTC Therapeutics' Sepiapterin in PKU Treatment Justifies Buy Rating
PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July
PTC Therapeutics Shares Are Trading Higher After the Company Announced Phase 3 APHENITY Trial Results.
PTC Therapeutics Announces Phase 3 APHENITY Trial Results: Over 97% Of Subjects Participating In The Phe Tolerance Protocol Of The APHENITY Open-Label Extension Study Demonstrate The Ability To Liberalize Their Diet While On Sepiapterin Treatment,...
